LOGIN  |  REGISTER
Chimerix
Chimerix

Alphatec to Participate in Upcoming Investor Conferences

November 01, 2023 | Last Trade: US$9.06 0.18 -1.95

CARLSBAD, Calif. / Nov 01, 2023 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor events:

  • The Stifel Healthcare Conference at the Lotte New York Palace Hotel in New York, NY, with a fireside chat at 3:00pm ET on November 14, 2023
  • The Jefferies London Healthcare Conference at the Waldorf Hilton in Aldwych, London, with a fireside chat at 2:30pm GMT on November 16, 2023
  • The Piper Sandler Healthcare Conference at the Lotte New York Palace Hotel in New York, NY, with a fireside chat at 12:00pm ET on November 28, 2023
  • The Truist Securities MedTech West Coast Bus Tour will visit ATEC Headquarters at 10:00am PT on December 6, 2023
  • The Stifel Medtech Madness West Coast Bus Tour at the Montage Laguna Beach in Laguna Beach, CA, with a fireside chat at 10:15am PT on December 11, 2023

Webcasts of the conference presentations and archived recordings will be available in the Investor Relations Section of the Company’s website.

About ATEC

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC’s Organic Innovation MachineTM is focused on developing new approaches that integrate seamlessly with the Company’s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC’s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com.

Viking Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB